According to the company, DepoVax vaccines are readily amenable to commercialization. They can be manufactured in large batches, and are well suited for large scale distribution and long term storage. DepoVax vaccines are packaged and stored in a dry form, ensuring the stability of antigens which can otherwise be unstable in aqueous formulations.
DepoVax has been tested in pandemic influenza and therapeutic cancer models. The research shows DepoVax-vaccines deliver effective, long lasting results with only one dose.
Randal Chase, president and CEO of ImmunoVaccine Technologies (IVT), said: “An effective and easy-to-administer DepoVax vaccine would be a valuable tool for health authorities dealing with a pandemic and we are planning to take this into the clinic as soon as possible.”